Method of treating cancer and bone cancer pain
This invention is directed to the treatment of cancer, particularly lung cancer, breast cancer, melanoma, renal cell carcinoma, thyroid cancer that has metastasized to the bone. The invention is also directed to a method for treating bone cancer pain in an individual in need of such treatment comprising administering to the individual an effective amount of a compound of Formula I.
1. A method inhibiting bone resorption in a patient in need of such treatment, comprising administering to the patient a therapeutically effective amount of Compound 1:
or a pharmaceutically acceptable salt thereof, optionally as a pharmaceutical composition comprising Compound 1 or a pharmaceutically acceptable salt thereof, wherein the patient has lung cancer, breast cancer, renal cell carcinoma, thyroid cancer, or ovarian cancer.
2. The method of claim 1 , wherein the patient has lung cancer.
3. The method of claim 1 , wherein the patient has breast cancer.
4. The method of claim 1 , wherein the patient has renal cell carcinoma.
5. The method of claim 1 , wherein the patient has thyroid cancer.
6. The method of claim 1 , wherein Compound 1 is administered as the pharmaceutical composition.
7. The method of claim 6 , wherein the pharmaceutical composition is a tablet.
8. The method of claim 1 , wherein the patient has ovarian cancer.
9. A method for reducing metastatic bone lesions in a patient in need of such treatment, comprising administering to the patient a therapeutically effective amount of Compound 1:
or a pharmaceutically acceptable salt thereof, optionally as a pharmaceutical composition comprising Compound 1 or a pharmaceutically acceptable salt thereof, wherein the patient has metastatic bone lesions associated with lung cancer, breast cancer, renal cell carcinoma, thyroid cancer, or ovarian cancer.
10. The method of claim 9 , wherein Compound 1 is administered as the L-malate salt.
11. A method of reducing bone pain in patients with melanoma, comprising administering to the patient 100 mg of Compound 1 as the L-malate salt: